Kiyofumi Kaneshiro - PeptiDream Ex CFO
| PPTDFDelisted Stock | USD 17.00 0.00 0.00% |
Insider
Kiyofumi Kaneshiro is Ex CFO of PeptiDream
| Phone | 81 4 4270 1300 |
| Web | https://www.peptidream.com |
PeptiDream Management Efficiency
PeptiDream's management efficiency ratios could be used to measure how well PeptiDream manages its routine affairs as well as how well it operates its assets and liabilities.PeptiDream has accumulated 21.64 B in total debt with debt to equity ratio (D/E) of 0.87, which is about average as compared to similar companies. PeptiDream has a current ratio of 2.38, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist PeptiDream until it has trouble settling it off, either with new capital or with free cash flow. So, PeptiDream's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like PeptiDream sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for PeptiDream to invest in growth at high rates of return. When we think about PeptiDream's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Mark Vignola | Terns Pharmaceuticals | 46 | |
| Marine Popoff | Hookipa Pharma | N/A | |
| Lena MoranAdams | Telix Pharmaceuticals Limited | N/A | |
| Robert Ho | Third Harmonic Bio | 49 | |
| Joseph McGuire | MAIA Biotechnology | 66 | |
| Julie Person | Third Harmonic Bio | 50 | |
| Demetrios MD | Inozyme Pharma | N/A | |
| James Spudich | Cytokinetics | 82 | |
| Amy Conrad | Tyra Biosciences | N/A | |
| Oxana Beskrovnaya | Dyne Therapeutics | 63 | |
| Darin Weber | ProKidney Corp | 56 | |
| Meredith Crowe | Telix Pharmaceuticals Limited | N/A | |
| Eric MD | Acumen Pharmaceuticals | 69 | |
| Hiroomi MD | Tyra Biosciences | 60 | |
| Jyoti BappSc | Telix Pharmaceuticals Limited | N/A | |
| John MD | Lixte Biotechnology Holdings | 87 | |
| Joern Aldag | Hookipa Pharma | 65 | |
| Hao Ede | Innovent Biologics | 64 | |
| Klaus Orlinger | Hookipa Pharma | 46 | |
| BSc BSc | Telix Pharmaceuticals Limited | N/A | |
| Joseph MD | ProKidney Corp | N/A | |
Management Performance
| Return On Equity | 0.0023 | |||
| Return On Asset | -0.0067 |
PeptiDream Leadership Team
Elected by the shareholders, the PeptiDream's board of directors comprises two types of representatives: PeptiDream inside directors who are chosen from within the company, and outside directors, selected externally and held independent of PeptiDream. The board's role is to monitor PeptiDream's management team and ensure that shareholders' interests are well served. PeptiDream's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, PeptiDream's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Yuko Okimoto, Ex Department | ||
| Keiichi Masuya, Ex COO | ||
| Kiyofumi Kaneshiro, Ex CFO | ||
| Patrick Reid, Chief Scientific Officer, Managing Director, Manager of RandD and Director | ||
| Toshiyuki Iwata, Head Relations |
PeptiDream Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is PeptiDream a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0023 | |||
| Return On Asset | -0.0067 | |||
| Profit Margin | 0 % | |||
| Operating Margin | (0.03) % | |||
| Current Valuation | 1.74 B | |||
| Shares Outstanding | 129.83 M | |||
| Shares Owned By Insiders | 28.01 % | |||
| Shares Owned By Institutions | 44.96 % | |||
| Price To Earning | 38.54 X | |||
| Price To Book | 9.39 X |
Currently Active Assets on Macroaxis
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Other Consideration for investing in PeptiDream Pink Sheet
If you are still planning to invest in PeptiDream check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the PeptiDream's history and understand the potential risks before investing.
| Transaction History View history of all your transactions and understand their impact on performance | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes |